Linkers for use in antibody drug conjugates
AssigneeOrum Therapeutics Inc.
InventorsNathan FISHKIN, Chen BAI, Khuloud TAKROURI, Peter U. PARK
Life of this patent
Estimating the term…
Abstract
The present disclosure provides traceless linkers, which can link an inducer of protein-protein interaction to a cell binding agent. Also provided are compositions comprising the linked compounds. The compounds and compositions are useful for treating diseases such as cancer in subjects in need thereof.
Claims117
A conjugate of formula (XXXII):
- or a pharmaceutically acceptable salt thereof, wherein:
- a is from 1 to 10;
- A′ is
- wherein
- n is 0 or 1;
- each Y is independently S or 0;
- indicates the point of attachment to R1;
- and
- indicates the point of attachment to the methylene group;
- R1, together with A′, is a compound that induces a protein-protein interaction;
- R2 is selected from hydrogen, a group that provides stability to R1-A′, a group that provides solubility to R1-A′, and a group that provides stability and solubility to R1-A′;
- L is a cleavable linker;
- and
- Bm is a binding moiety that is capable of specifically binding to a protein.
A conjugate of formula (XX):
- or a pharmaceutically acceptable salt thereof, wherein:
- a is from 1 to 10;
- n is 0 or 1;
- R1 is a compound that induces a protein-protein interaction;
- R2 is selected from hydrogen, —(CH2CH2O)v—CH3, C2-C6alkenyl, C1-C6alkyl;
- C2-C6alkynyl, benzyl, C3-C6cycloalkyl, and C3-C6cycloalkyl(C1-C3alkyl), wherein v is from 1 to 24;
- each Y is independently S or 0;
- L is a cleavable linker;
- and
- Bm is a binding moiety that is capable of specifically binding to a protein.
A compound of formula (XXII):
- or a pharmaceutically acceptable salt thereof, wherein:
- n is 0 or 1;
- R1 is a compound that induces a protein-protein interaction;
- R2 is selected from hydrogen, —(CH2CH2O)v—CH3, C2-C6alkenyl, C1-C6alkyl;
- C2-C6alkynyl, benzyl, C3-C6cycloalkyl, and C3-C6cycloalkyl(C1-C3alkyl), wherein v is from 1 to 24;
- each Y is independently S or O;
- and
- L* is a cleavable linker precursor that conjugates to the binding moiety.
A compound of formula (XXXI):
- or a pharmaceutically acceptable salt thereof, wherein:
- A′ is
- wherein
- n is 0 or 1;
- each Y is independently S or 0;
- indicates the point of attachment to R1;
- and
- indicates the point of attachment to the methylene group;
- R1, together with A′, is a compound that induces a protein-protein interaction;
- R2 is selected from hydrogen, a group that provides stability to R1-A′, a group that provides solubility to R1-A′, and a group that provides stability and solubility to R1-A′;
- and
- L is a cleavable linker precursor that conjugates to the binding moiety.
A method for preparing a conjugate of formula (XXXII):
- or a pharmaceutically acceptable salt thereof, wherein:
- a is from 1 to 10;
- A′ is
- wherein
- n is 0 or 1;
- each Y is independently S or 0;
- indicates the point of attachment to R1;
- and
- indicates the point of attachment to the methylene group;
- R1, together with A′, is a compound that induces a protein-protein interaction;
- R2 is selected from hydrogen, a group that provides stability to R1-A′, a group that provides solubility to R1-A′, and a group that provides stability and solubility to R1-A′;
- L is a cleavable linker;
- and
- Bm is a binding moiety that is capable of specifically binding to a protein;
- the method comprising:
- reacting a compound of (XXXI)
- or a pharmaceutically acceptable salt thereof, wherein:
- A′, R1, and R2 are as defined above and
- L* is a cleavable linker precursor;
- with a binding moiety that is capable of specifically binding to a protein.
The method of 108, wherein R1 has the formula:
- POI-L100-CBN;
- wherein:
- POI is a compound that binds to a protein of interest;
- L100 is a PROTAC linker;
- and
- CBN is a cereblon binding moiety.
A method of delivering a conjugate of formula (XXXII):
- or a pharmaceutically acceptable salt thereof to a cell, wherein:
- a is from 1 to 10;
- A′ is
- wherein
- n is 0 or 1;
- each Y is independently S or 0;
- indicates the point of attachment to R1;
- and
- indicates the point of attachment to the methylene group;
- R1, together with A′, is a compound that induces a protein-protein interaction;
- R2 is selected from hydrogen, a group that provides stability to R1-A′, a group that provides solubility to R1-′A, and a group that provides stability and solubility to R1-A′;
- L is a cleavable linker;
- and
- Bm is a binding moiety that is capable of specifically binding to a protein;
- the method comprising contacting the cell with a conjugate of formula (XXXII), or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.